Acrux Limited is an Australian specialty pharmaceutical company focused on developing, registering, and commercialising generic and topically applied pharmaceutical products. The company leverages proprietary transdermal and topical delivery technologies to bring treatments to market, with a primary emphasis on the US. Its product portfolio includes brands such as AXIRON, ELLAVIE, EVAMIST, and RECUVYRA, targeting conditions like menopausal symptoms, acne, and pain management. Acrux Limited operates as a pooled development fund, investing in pharmaceutical businesses and advancing drug delivery innovations. The company is headquartered in West Melbourne and is listed on multiple exchanges, including the CHI-X Market Australia – Limit Venue, where its shares are traded under the symbol ACR. As a participant in the Health Technology sector, Acrux Limited plays a role in expanding access to cost-effective, non-invasive pharmaceutical solutions for patients and healthcare providers.